Yang 2011.
Methods | Aim: to treat early post‐stroke depression | |
Participants | Country: China Setting: inpatient Stroke: all pathological types, clinical diagnosis plus confirmation of lesion on imaging, no previous psychiatric and psychological disorders, age < 75 years old, stroke onset time < 72 hours, NIHSS score: 4 to 19 Mood: HAMD ≥ 8 Treatment: 20 people, mean age 64 ± 8 years, 8 men Control: 22 people, mean age 64 ± 10 years, 13 men Note inconsistency between abstract (20 in treatment and 22 in control, but in tables of results, there are 22 in treatment and 20 in control). We have used the data from the abstract Excluded: functional psychiatric disorder, functional depression, psychoactive substance and addictive substance induced psychiatric disorders, infectious disease, severe cognitive impairment to affect communication, severe aphasia to affect communication, severe cardiac, pulmonary, hepatic and renal function impairment, previous organic brain disease such as brain tumour, or symptomatic stroke, encephalitis |
|
Interventions | Treatment: paroxetine 20 mg daily plus usual stroke care Control: usual stroke care Duration of treatment: at least 3 months Duration of follow‐up: 0 |
|
Outcomes | HAMD score, IL‐1β and IL‐6 level Death AEs not reported |
|
Funding source | Source of funding: local scientific academic fund | |
Notes | − | |
Risk of bias | ||
Bias | Authors' judgement | Support for judgement |
Random sequence generation (selection bias) | Unclear risk | Quote: "Case sequence" randomisation |
Allocation concealment (selection bias) | Unclear risk | Not described |
Blinding of participants and personnel (performance bias) All outcomes | High risk | No placebo |
Blinding of outcome assessment (detection bias) All outcomes | Unclear risk | Not described |
Incomplete outcome data (attrition bias) All outcomes | Low risk | No dropouts |
Selective reporting (reporting bias) | Unclear risk | No protocol |
Other bias | Low risk | No difference in baseline |